Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting

Endocrine Practice

Volumn 17, Issue 6, 2011, Pages 845-852

  Davis, Stephen ^a   Wei, Wenhui ^b   Garg, Satish ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISPOSABLE EQUIPMENT; DRUG DOSAGE FORM COMPARISON; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SYRINGE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MANAGED CARE PROGRAMS; MATERIALS TESTING; MEDICATION ADHERENCE; MIDDLE AGED; NEEDLES; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; SYRINGES; UNITED STATES;

EID: 84855846339     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10401.OR     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national esti-mates on diabetes in the United States 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2008. http://www.cdc.gov/diabetes/pubs/pdf/ndfs- 2007.pdf. Accessed for verif-cation July 6, 2011.
2. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225-2229.
3. American Diabetes Association. Standards of medi-cal care in diabetes\-2010 [published correction appears in Diabetes Care. 2010;33:692]. Diabetes Care. 2010;33 (suppl 1):S11-S61.
4. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glyce-mic control improving in U.S. adults? Diabetes Care. 2008; 31:81-86.
5. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin. 2009;25:1605-1613.
6. Riddle MC, Rosenstock J, Gerich J (Insulin Glargine 4002 Study Investigators). The treat-to-target trial: ran-domized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26: 3080-3086. (Pubitemid 37339502)
7. Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23:3105-3112.
8. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the Translating Research Into Action for Diabetes insulin starts project. Diabetes Care. 2010;33:733-735.
9. Korytkowski M, Bell D, Jacobsen C, Suwannasari R (FlexPen Study Team). A multicenter, randomized, open-label, comparative, two-period crossover trial of prefer-ence, effcacy, and safety profles of a preflled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848. (Pubitemid 37510593)
10. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26:1498-1505. (Pubitemid 39572159)
11. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120:172-179.
12. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen com-pared with vial and syringe and FlexPen. Diabetes Educ. 2009;35:789-798.
13. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device SoloStar versus Flexpen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29:650-660. (Pubitemid 47016637)
14. Schwartz S, Vlajnic A. Validation of the SoloSTAR insu-lin pen. Diabetes Technol Ther. 2008;10:351-357.
15. Hermanns N, Kulzer B, Haak T. Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. Diabetes Technol Ther. 2008;10:322-327.
16. Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz M. Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin. 2010;26: 901-905.
17. Rosenbaum PR, Rubin DB. The central role of the pro-pensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
18. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231-238.
19. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medica-tion adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29(6, pt 1):1294-1305. (Pubitemid 351172225)
20. Hertz RP, Unger AN, Lustik MB. Adherence with phar-macotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27:1064-1073. (Pubitemid 41262464)
21. Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy Adv Ther. 2009;26:838-846.
22. Asakura T, Seino H, Nakano R, et al. A comparison of the handling and accuracy of syringe and vial versus preflled insulin pen (FlexPen). Diabetes Technol Ther. 2009;11: 657-661.
23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-ran-domized control group. Stat Med. 1998;17:2265-2281.